Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.

ABSTRACT:

Background

Many patients receiving adjuvant endocrine therapy (ET) for breast cancer experience side effects and reduced quality of life (QoL) and discontinue ET. We sought to describe these issues and develop a prediction model of early discontinuation of ET.

Methods

Among patients with hormone receptor-positive and HER2-negative stage I-III breast cancer of the Cancer Toxicities cohort (NCT01993498) who were prescribed adjuvant ET between 2012 and 2017, upon stratification by menopausal status, we evaluated adjuvant ET patterns including treatment change and patient-reported discontinuation and ET-associated toxicities and impact on QoL. Independent variables included clinical and demographic features, toxicities, and patient-reported outcomes. A machine-learning model to

SUBMITTER: Balazard F 

PROVIDER: S-EPMC10483331 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature